![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 21, 2021 11:30:03 AM
Topics of the ongoing disputes include that, according to Relief, NeuroRx is refusing to share data from its recently completed Phase IIb/III clinical trial with Relief. These data must be made available to Relief in accordance with the provisions of the cooperation agreement.
In addition, NeuroRx has denied its contractors dealing with Aviptadil development issues to provide Relief with information that Relief needs for the development of its Aviptadil product in its sales territories (including the EU and the UK). As a result, Relief has reportedly believed that NeuroRx has defaulted on its obligations under the Collaboration Agreement and that NeuroRx's failure to develop and implement a clinical and regulatory strategy for its territories will severely affect Relief's ability to develop and implement a clinical and regulatory strategy for its territories.
NeuroRx also claims that Relief owes approximately $ 4 million in unpaid bills. "Unfortunately, many of these alleged expenses were not backed up by valid, verifiable invoices", Relief commented in a press release. There is also disagreement between the parties, whether expenses that exceed the budget set in the cooperation agreement are reimbursable.
IMO, both should consider what they will lose if they don't come to a setlement in no time.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM